Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment
By Ben Glickman
Shares of Bluebird bio fell after the company's sickle-cell disease treatment received a black-box warning and was announced at a higher price point than a competitor's treatment.
The stock was down 41% to $2.84 on Friday. Shares are down 60% this year.
The company's Lyfgenia was approved by the Food and Drug Administration for the treatment of sickle-cell disease. The FDA also approved Casgevy, a sickle-cell treatment developed by Vertex Pharmaceuticals and CRISPR Therapeutics using Crispr gene-modification technology.
The FDA said that Lyfgenia would include a black-box warning related to certain cases of blood cancer in patients treated with the drug.
Bluebird said the treatment would come with a $3.1 million price tag, compared with the $2.2 million price for Casgevy.
Evercore analysts said in a research note that the announcements gave Casgevy an advantage because of its lack of black-box label and lower price.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 08, 2023 15:56 ET (20:56 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing